By Pharm. Gbenga Falabi FPSN, FSPSMN
(Guest Writer)
Nigeria’s pharmaceutical market is at a critical inflection point. The population continues to grow rapidly, chronic illnesses are on the rise, and government initiatives such as the expansion of the National Health Insurance Authority (NHIA) have created a larger-than-ever need for access to quality medicines. These trends suggest strong growth potential—but that growth will not be sustainable if we continue to ignore a vital truth: Ethical selling and compliance are not regulatory burdens. They are strategic imperatives.
The 2025 Induction Ceremony and Investiture of Fellows of the Society for Pharmaceutical Sales and Marketing of Nigeria (SPSMN), presented the opportunity to reflect deeply on this theme. My submission was simple: the commercial health of our industry is tied directly to the ethical strength of its practices and the discipline of its compliance culture.
The market we serve—and the one we’re becoming
The Nigerian pharmaceutical industry is vast and varied. It includes importers (still accounting for nearly 70 per cent of the market), local manufacturers, distributors, retail pharmacies, hospital channels, and PPMVs. It’s a supply chain anchored by regulatory authorities such as NAFDAC and PCN, but increasingly shaped by the preferences, perceptions, and power of the end-users: the HCPs and the Nigerian patient.
And yet, with all its promise, the market remains beset by old and new problems—counterfeit medicines, non-compliance, unethical promotional practices, distrust, and weak enforcement of standards. These issues don’t just affect companies. They harm patients, erode public confidence, and ultimately weaken our industry’s ability to grow.
What I propose is a new ethos—one in which ethical selling and compliance are seen not as afterthoughts but as the bedrock of our collective future.
What ethical selling really means
Let’s be clear. Ethical selling is not theoretical—it is practical. It means:
Promoting medicines responsibly.
Never placing personal or corporate gain above patient well-being.
Avoiding manipulative or misleading marketing.
Rejecting bribery, kickbacks, and pressure-based prescribing.
Always putting science before slogans.
Unethical practices do more than stain reputations. They lead to adverse health outcomes, inflated treatment costs, resistance to therapy, and loss of market credibility. And in a country where trust in healthcare systems is already fragile, that damage can be irreversible.
Conversely, companies that uphold ethical standards experience stronger brand loyalty, deeper stakeholder trust, and more durable growth trajectories.
Compliance is strategy
Too often, compliance is treated as a checklist—something to endure, not embrace. That mindset must change.
Compliance is not only about obeying laws—it’s about building a culture of accountability, transparency, and consistency. From regulatory filings to marketing authorizations, from SOPs to field rep training, a strong compliance framework is a signal to regulators, partners, and patients alike: we take our role seriously.
True compliance gives you:
Operational clarity in a volatile regulatory environment.
Protection from costly penalties or reputational fallout.
Respect from global partners, regulators, and discerning customers.
The Fusion of ethics and compliance
These two concepts—ethics and compliance—should no longer live in separate boxes. They are strongest when merged into a shared business philosophy.
This begins with people. Our sales teams must be trained, retrained, and empowered to embody ethical values. Field staff are our brand ambassadors. If they bend the rules, the company breaks its promise.
We must:
Build capacity with ethics-oriented training.
Create open channels for reporting violations.
Monitor activities regularly and fairly.
Reward ethical behavior, not just sales volumes.
When sales strategy aligns with regulatory expectation, you don’t lose competitive edge—you sharpen it.
Competitive advantage built on trust
In a skeptical market like ours—where public perception often tilts toward doubt—trust is currency.
There are Nigerian brands today that outsell multinational products not because they’re cheaper or louder, but because they’re trusted. They engage transparently with health professionals, resolve crises openly, and stand firm on product quality.
One example: when a prominent antimalarial brand faced regulatory scrutiny over counterfeit fears, it was the company’s track record of ethical engagement that bought them the benefit of the doubt, saved market share, and eventually led to a full reputational rebound.
The takeaway? Ethics isn’t just about doing the right thing—it’s about doing the smart thing.
Bridging the gap—together
If we are truly serious about growing the pharmaceutical market in Nigeria—about expanding access, improving outcomes, and building strong commercial organizations—we must bridge the gap between what is profitable and what is principled.
It is possible to do both. It is necessary to do both.
To industry leaders, I say: invest in ethical leadership.
To sales and marketing professionals: hold yourselves to higher standards.
To regulators: enforce rules evenly, transparently, and without fear or favor.
To SPSMN and its members: lead from the front—train, advocate, and set the tone.
The future of our market depends on it.
Pharm. ’Gbenga Falabi, FPSN, FSPSM is the general manager, Aquatix Pharmaceuticals Limited, Ikeja. He was a former national chairman, National Association of Industrial Pharmacists (NAIP) and immediate national secretary, Pharmaceutical Society of Nigeria. He made this presentation as the keynote speaker, the Society for Pharmaceutical sales and marketing of Nigeria’s 2025 Induction Ceremony and Investiture of Fellows
